Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
about
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerEvolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223Targeting bone physiology for the treatment of metastatic prostate cancerRadionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerPhase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Bone-targeting agents in prostate cancer.The best of both worlds - managing the cancer, saving the bone.Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.Radium-223 for the treatment of castration-resistant prostate cancer.Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experienceThe use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killingStrengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.Effectiveness of radioisotope therapy in bone metastases, based on personal experience.Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.Painful boney metastases.Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastasesBone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerBone-Targeted Imaging and Radionuclide Therapy in Prostate CancerMay bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trialThe influence of Sm-153 therapy on bone marrow functionThe role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.Radium-223 for the treatment of prostate cancer.Burden of skeletal-related events in prostate cancer: unmet need in pain improvement.Emerging drugs for the treatment of bone metastasis.Bone marrow recovery following use of systemic (153)Sm-lexidronam and (89)Sr-chloride for bone pain palliation after myelosuppressive therapy.Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study.153Sm: its use in multiple myeloma and report of a clinical experience
P2860
Q26752785-F4A3CDEA-834B-4E72-8377-2A1A0A9047CEQ26861575-AE486AB2-F002-45E9-945A-357CDE750766Q26863249-7A9756A9-6AED-41A5-8462-70E60EE858EAQ28079918-FEACEF37-E4F8-46A9-8447-8CDE1BECC772Q33387322-9397412B-5966-4872-883F-741BC9843E00Q33405335-E1EF644E-7664-4136-8D9D-691F70C27AC3Q33864723-1167EC78-A4CF-4E16-9256-7896A850CC46Q33920055-3DC13D2A-0BA5-419D-AC1B-8E6BF14E5933Q35057029-FEA36AA7-C17A-4665-8569-EA1A723700A9Q35653986-A5EDCA49-E368-47EE-A949-400CAE578772Q35660931-C5B75641-CDEC-4887-AE3C-298D3EA4D574Q35917106-35884EF5-8EB0-4F53-988F-8955642D8A26Q36126003-C65791FA-CDC8-452C-9C08-E10515B08FD9Q36297804-6DA34CD1-CCB0-441D-B06F-FCF7C21AF8CEQ36840731-17A2116B-1B34-4129-B85A-728E2F493984Q36942561-63056855-B210-4D2E-9EF3-F82E2445F9AAQ37004657-FBB23CF9-37E3-4749-9AF0-016D7CF2FE88Q37011060-F1A5DC28-DCCE-4DA6-BB93-D3508C33A1BCQ37103630-E5B7EC7A-7583-4762-B753-CE13A0A040FDQ37166534-C863162D-56F5-4FEB-8630-2310C48108D7Q37198970-942591D0-4662-49AA-82D9-F5074C78C944Q37390666-0FD484C2-FE31-4BC1-821B-DC538B540EFDQ37402627-EF95242F-30A9-40BD-B24F-8486EFC158F5Q37662701-723C20BF-ACCA-4BB7-86EC-3753F4D716CBQ37684364-E16A986A-A534-4D17-A876-2DD77E0F5ECAQ37727656-331EC137-EA8D-4717-BD81-81977FDF47B7Q38001275-51E4E1EC-B77C-4381-81E9-4B0E611F4002Q38073823-66DCAF71-6038-4B2B-AC5F-E116F29D0345Q38255741-ED307593-1D25-4E52-BA5B-F904B5501726Q38538263-23049EDB-6E38-41F4-9DBF-D05C8F7235CCQ42167680-072E9E88-968C-40F6-8E31-598067CC9E02Q43146234-B13CE4D2-FBB7-421A-95BC-8DBCC3B62FF0Q47684583-8F4AE4F7-F20C-47F4-8FED-C210B254FDB2Q58449064-399BA1BB-7479-4513-88DF-00939563FFFA
P2860
Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Safety and efficacy of repeat ...... nts with metastatic bone pain.
@ast
Safety and efficacy of repeat ...... nts with metastatic bone pain.
@en
type
label
Safety and efficacy of repeat ...... nts with metastatic bone pain.
@ast
Safety and efficacy of repeat ...... nts with metastatic bone pain.
@en
prefLabel
Safety and efficacy of repeat ...... nts with metastatic bone pain.
@ast
Safety and efficacy of repeat ...... nts with metastatic bone pain.
@en
P2093
P356
P1433
P1476
Safety and efficacy of repeat ...... nts with metastatic bone pain.
@en
P2093
Donald P Quick
Oliver Sartor
Peter J Ell
Robert H Reid
P304
P356
10.1002/CNCR.22431
P407
P577
2007-02-01T00:00:00Z